Join us at HFRI Research Symposium! We’re already at 40 abstracts and counting!! Registration below!

HFpEF is marked by elevated LV filling pressures due to diastolic dysfunction. This review explores how intrathoracic volume & pressure—affected by posture, gravity, obesity, & exercise—shape cardiac filling & highlight research gaps (link.springer.com/article/10.100…). Josephine Harrington, MD

The vast majority of patients with HFpEF have cardiometabolic disease driven by adipose tissue at the core. Lines of evidence continue to support this adipokine hypothesis. The inimitable Milton Packer provides a deeper understanding of the evidence in this timely perspective

🔥A must-read masterpiece by Eric Topol on the PROTEIN PANDEMIC. 📉 Evidence shows: most people already meet protein needs. Extra ≠ better & probable ↑ risk (CV + kidney harm⚡️) Teens/young adults—don’t fall for the protein hype on your instgram feeds erictopol.substack.com/p/our-preoccup…

Sub-analysis of the BEST trial showing IVUS-guided PCI equivalent to CABG! An excellent review of the paper by Gregg W. Stone MD discussed how we can be better at what we do and be equivalent to bypass. In the order of importance, just in my opinion! 1-Intravscular imaging. A

Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease businesswire.com/news/home/2025…

September 16, 1977, Andreas Gruentzig performed the 1st coronary angioplasty in Zurich. Below is the story, told by the 1st patient himself, Adolph Bachman, and his doctor, Bernhard Meier. This was the birth, not just of interventional cardiology, but a whole new branch of

Wow, HF Prevention Makes Front Page of The Lancet! Watershed moment to prioritize early screening, diagnosis, & treatment of HF 🔍 Identify Stage B “pre-HF” 💻 Quantify risk 🩺 Address modifiable RFs 👩🏽‍⚕️ Implement #CKM therapies 🫱🏾‍🫲🏽 Collaborative care thelancet.com/series-do/hear…

👏 Huge thank you to Gregg Fonarow MD for leading this amazing effort! 🚨Enormous & increasing burden of #HF globally 🏆Enormous opportunity with #GDMTworks 🎯Let's make these data count HFSA #HFSA2025 Journal of Cardiac Failure BiykemBozkurt Nosheen Reza, MD, MS Clyde Yancy, MD, MSc Boback Ziaeian 🤦🏻‍♂️ Ryan J Tedford MD Tariq Ahmad MD MPH

America’s heart failure epidemic is getting worse cardiovascularbusiness.com/topics/clinica… HFSA Journal of Cardiac Failure

Presenting late-breaking VITAL-HF results Sunday at HFSA : multicenter RCT (n=178, 7 US sites) of a remote, digital GDMT titration program vs usual care over 6 months. Primary: change in HFC score; key secondaries: KCMO, dose attainment, safety. #HFSA2025

Corstasis Therapeutics and U.S. Heart and Vascular® Collaboration Will Seek to Improve Heart Failure Care with ENBUMYST™ (Bumetanide Nasal Spray) - businesswire.com/news/home/2025… Brian Kolski,MD Eric Adler

Bumetanide nasal spray, now FDA approved. One use cartridge. What’s the use case in your practice? #HFSA2025

It’s #HFSA2025 time! Celebrating 30 years of this amazing organization that brought so many of us together! HFSA Marvelous pre-mtg day w/Journal of Cardiac Failure team, packed Device Day & seeing friends & colleagues Tomorrow 💜💜💜 for patients!!

#HFSA2025 plenary & open session now!! Celebrating 30 years!!!! HFSA Journal of Cardiac Failure Congratulations to award winners, outgoing president Michael Felker, Dr Amanda Vest for chairing ASM this year & so many others!

#WordsMatter Journal of Cardiac Failure #FunctionNotFailure @hfsa

🚨 A new, practical framework for evaluating the economic value of cardiovascular drugs, devices, and preventive strategies Just published in JACC Journals and Circulation Here’s what’s new, why it matters, and how it will shape care. 🧵

Heart failure incidence, cost increasing in US healio.com/news/cardiolog… HFSA Journal of Cardiac Failure Healio Department of Medicine at UCLA Health UCLA Health News

Most Updated Global Burden of Cardiovascular Disease now out in JACC Journals 80% (!) of CV disease burden is attributable to modifiable RFs Top modifiable risks in 2023: ⚠️ High systolic BP ⚠️ Dietary risks ⚠️ High LDL cholesterol ⚠️ Air pollution 🔗 jacc.org/doi/10.1016/j.…